Radio Frequency Wireless Technology in Medical Devices; Guidance for Industry and Food and Drug Administration Staff; Availability, 49529-49530 [2013-19686]
Download as PDF
Federal Register / Vol. 78, No. 157 / Wednesday, August 14, 2013 / Notices
in accordance with section 503(g) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 353(g)) and 21 CFR 3.4. This
will consolidate primary responsibility
for regulating wound care products
containing live cells in CBER.
II. Web page Listing CDRH
Applications Transferred to CBER and
Contact Information
FDA has created a Web page listing
the premarket approval applications and
humanitarian device exemptions in
CDRH that are being transferred to
CBER. Sponsors of these products are
encouraged to consult the Web page to
find new contact information. The Web
page address is: https://www.fda.gov/
BiologicsBloodVaccines/
CellularGeneTherapyProducts/
ucm356173.htm.
Commencing immediately, submitters
should send submissions to: Document
Control Center, HFM–99, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 1401
Rockville Pike, suite 200N, Rockville,
MD 20852–1448. Contact for questions
on submissions: Patrick Riggins, Office
of Cellular, Tissue and Gene Therapy,
Center for Biologics Evaluation and
Research, WOC1, Rm. 234N (HFM–705),
1401 Rockville Pike, Rockville, MD
20852–1448, 301–827–5366,
patrick.riggins@fda/hhs.gov.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–19685 Filed 8–13–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2006–D–0300] (formerly
Docket No. 2006D–0504)
Radio Frequency Wireless Technology
in Medical Devices; Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Radio Frequency Wireless Technology
in Medical Devices; Guidance for
Industry and Food and Drug
Administration Staff.’’ This guidance
document is intended to assist industry
and FDA staff in identifying and
appropriately addressing specific
considerations related to the
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:16 Aug 13, 2013
Jkt 229001
incorporation and integration of radio
frequency (RF) wireless technology in
medical devices. This guidance
discusses issues that may affect the safe
and effective use of medical devices that
incorporate RF wireless technology,
including selection of wireless
technology, quality of service,
coexistence, security, and
electromagnetic compatibility, and
provides recommendations for
information to be included in FDA
premarket submissions for such devices.
DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: Submit written requests for
single copies of the guidance document
entitled ‘‘Radio Frequency Wireless
Technology in Medical Devices;
Guidance for Industry and Food and
Drug Administration Staff’’ to the
Division of Small Manufacturers,
International and Consumer Assistance,
Center for Devices and Radiological
Health (CDRH), Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4613, Silver Spring,
MD 20993–0002 or Office of
Communication, Outreach, and
Development (HFM–40), Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852–1448. Send one
self-addressed adhesive label to assist
those offices in processing your request,
or fax your request to CDRH at 301–
847–8149. See the SUPPLEMENTARY
INFORMATION section for information on
electronic access to the guidance.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Donald Witters, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1130, Silver Spring,
MD 20993–0002, 301–796–2483; or
Stephen Ripley, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, Suite 200N, Rockville,
MD 20852, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA developed this guidance
document to assist industry, systems
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
49529
and service providers, consultants, FDA
staff, and others involved in the design,
development, and evaluation of RF
wireless technology in medical devices.
The use and deployment of RF wireless
technology in and around medical
devices is an increasing concern
because the electromagnetic
environments where medical devices
are used might contain many sources of
RF energy, and the RF wireless
emissions from one product or device
could potentially affect the function of
another. The guidance recommends that
manufacturers address the potential
issues that relate to the incorporation of
RF wireless technology that may affect
the safe and effective use of medical
devices.
The draft guidance document and
comment period were announced in the
Federal Register on January 3, 2007 (72
FR 137). The comment period closed on
April 2, 2007. Over 25 companies,
numerous organizations, and many
individuals provided around 180
comments. FDA considered all of the
comments and revised the guidance
where appropriate.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on radio frequency
wireless technology in medical devices.
It does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statute
and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by using the
Internet. A search capability for all
CDRH guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov or the
CBER Internet site at https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceCompliance
RegulatoryInformation/Guidances/
default.htm. To receive ‘‘Radio
Frequency Wireless Technology in
Medical Devices; Guidance for Industry
and Food and Drug Administration
Staff,’’ you may either send an email
request to dsmica@fda.hhs.gov to
receive an electronic copy of the
document or send a fax request to 301–
847–8149 to receive a hard copy. Please
use the document number 1618 to
E:\FR\FM\14AUN1.SGM
14AUN1
49530
Federal Register / Vol. 78, No. 157 / Wednesday, August 14, 2013 / Notices
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 801 have been approved
under OMB control number 0910–0485;
the collections of information in 21 CFR
part 807, subpart E have been approved
under OMB control number 0910–0120;
the collections of information in 21 CFR
part 814 have been approved under
OMB control number 0910–0231; the
collections of information in 21 CFR
part 814, subpart H have been approved
under OMB control number 0910–0332;
and the collections of information in 21
CFR part 820 have been approved under
OMB control number 0910–0073.
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (See ADDRESSES).
It is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–19686 Filed 8–13–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Gastroenterology Regulatory
Endpoints and the Advancement of
Therapeutics; Public Workshop
AGENCY:
Food and Drug Administration,
tkelley on DSK3SPTVN1PROD with NOTICES
HHS.
ACTION:
Notice of public workshop.
The Food and Drug
Administration’s (FDA) Center for Drug
Evaluation and Research, in
cosponsorship with the American
College of Gastroenterology, the
American Gastroenterological
SUMMARY:
VerDate Mar<15>2010
16:16 Aug 13, 2013
Jkt 229001
Association, the Crohn’s and Colitis
Foundation of America, Inc., the North
American Society for Pediatric
Gastroenterology, Hepatology, and
Nutrition, and the Pediatric IBD
Foundation, is announcing a 2-day
public workshop entitled
‘‘Gastroenterology Regulatory Endpoints
and the Advancement of Therapeutics
(GREAT II).’’ Partners and stakeholders
planning the workshop also include
patients and representatives from the
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development at the National Institutes
of Health. The purpose of this workshop
is to provide a forum to consider issues
related to endpoints that can support
drug development in the following
disease areas: Pediatric and adult
inflammatory bowel diseases.
DATES: The public workshop will be
held on October 21 and 22, 2013, from
8:30 a.m. to 5 p.m.
ADDRESSES: The public workshop will
be held at the National Institutes of
Health, 31 Center Dr., Natcher
Conference Center, Building 45,
Bethesda, MD 20892–2178.
FOR FURTHER INFORMATION CONTACT:
Kevin Bugin, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–2302, FAX: 301–796–9905,
email: Kevin.Bugin@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: This
workshop will address endpoints for
registration trials. Stakeholders,
including industry sponsors, academia,
patients, and FDA, will be engaged to
address challenging issues related to
selection of endpoints and assessment
methodologies in registration trials for
products intended to treat adult and/or
pediatric inflammatory bowel disease.
The definition and measurement of
treatment benefit in Crohn’s disease
registration trials, the role of existing
and future clinical outcome assessments
including development of patient
reported outcome measures, timing of
endpoint assessments, and dose-finding
strategies will be discussed. In addition,
there will be a followup to previous
workshop discussions of endpoints and
clinical trial design for ulcerative colitis
registration trials. Strategies and
methods to overcome the challenges of
developing drugs in pediatric
populations and facilitate the collection
of dosing, safety, and efficacy
information for drugs not currently
approved for use in children will be
discussed.
Participation in the Public Workshop:
Registration: There is no fee to attend
the public workshop, but attendees
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
must register in advance. Space is
limited, and registration will be on a
first-come, first-served basis. Persons
interested in attending this workshop
must register online at https://
www.great2.org before October 1, 2013.
For those without Internet access, please
contact Kevin Bugin (see FOR FURTHER
INFORMATION CONTACT) to register. Onsite
registration will not be available.
If you need special accommodations
due to a disability, please contact Kevin
Bugin (see FOR FURTHER INFORMATION
CONTACT) at least 7 days in advance.
Transcripts: Transcripts of the
workshop will be available for review at
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, and on the
Internet at https://www.regulations.gov
approximately 30 days after the
workshop. A transcript will also be
available in either hard copy or on CD–
ROM, after submission of a Freedom of
Information request. Send written
requests to the Division of Freedom of
Information (ELEM–1029), Food and
Drug Administration, 12420 Parklawn
Dr., Element Bldg., Rockville, MD
20857. Send faxed requests to 301–827–
9267.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–19684 Filed 8–13–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received within 30 days of this notice.
SUMMARY:
E:\FR\FM\14AUN1.SGM
14AUN1
Agencies
[Federal Register Volume 78, Number 157 (Wednesday, August 14, 2013)]
[Notices]
[Pages 49529-49530]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19686]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2006-D-0300] (formerly Docket No. 2006D-0504)
Radio Frequency Wireless Technology in Medical Devices; Guidance
for Industry and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Radio Frequency Wireless
Technology in Medical Devices; Guidance for Industry and Food and Drug
Administration Staff.'' This guidance document is intended to assist
industry and FDA staff in identifying and appropriately addressing
specific considerations related to the incorporation and integration of
radio frequency (RF) wireless technology in medical devices. This
guidance discusses issues that may affect the safe and effective use of
medical devices that incorporate RF wireless technology, including
selection of wireless technology, quality of service, coexistence,
security, and electromagnetic compatibility, and provides
recommendations for information to be included in FDA premarket
submissions for such devices.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: Submit written requests for single copies of the guidance
document entitled ``Radio Frequency Wireless Technology in Medical
Devices; Guidance for Industry and Food and Drug Administration Staff''
to the Division of Small Manufacturers, International and Consumer
Assistance, Center for Devices and Radiological Health (CDRH), Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4613,
Silver Spring, MD 20993-0002 or Office of Communication, Outreach, and
Development (HFM-40), Center for Biologics Evaluation and Research
(CBER), Food and Drug Administration, 1401 Rockville Pike, suite 200N,
Rockville, MD 20852-1448. Send one self-addressed adhesive label to
assist those offices in processing your request, or fax your request to
CDRH at 301-847-8149. See the SUPPLEMENTARY INFORMATION section for
information on electronic access to the guidance.
Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Donald Witters, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1130, Silver Spring, MD 20993-0002, 301-796-2483;
or Stephen Ripley, Center for Biologics Evaluation and Research (HFM-
17), Food and Drug Administration, 1401 Rockville Pike, Suite 200N,
Rockville, MD 20852, 301-827-6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA developed this guidance document to assist industry, systems
and service providers, consultants, FDA staff, and others involved in
the design, development, and evaluation of RF wireless technology in
medical devices. The use and deployment of RF wireless technology in
and around medical devices is an increasing concern because the
electromagnetic environments where medical devices are used might
contain many sources of RF energy, and the RF wireless emissions from
one product or device could potentially affect the function of another.
The guidance recommends that manufacturers address the potential issues
that relate to the incorporation of RF wireless technology that may
affect the safe and effective use of medical devices.
The draft guidance document and comment period were announced in
the Federal Register on January 3, 2007 (72 FR 137). The comment period
closed on April 2, 2007. Over 25 companies, numerous organizations, and
many individuals provided around 180 comments. FDA considered all of
the comments and revised the guidance where appropriate.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
Agency's current thinking on radio frequency wireless technology in
medical devices. It does not create or confer any rights for or on any
person and does not operate to bind FDA or the public. An alternative
approach may be used if such approach satisfies the requirements of the
applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
using the Internet. A search capability for all CDRH guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov or the CBER
Internet site at https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. To
receive ``Radio Frequency Wireless Technology in Medical Devices;
Guidance for Industry and Food and Drug Administration Staff,'' you may
either send an email request to dsmica@fda.hhs.gov to receive an
electronic copy of the document or send a fax request to 301-847-8149
to receive a hard copy. Please use the document number 1618 to
[[Page 49530]]
identify the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 801 have been approved under
OMB control number 0910-0485; the collections of information in 21 CFR
part 807, subpart E have been approved under OMB control number 0910-
0120; the collections of information in 21 CFR part 814 have been
approved under OMB control number 0910-0231; the collections of
information in 21 CFR part 814, subpart H have been approved under OMB
control number 0910-0332; and the collections of information in 21 CFR
part 820 have been approved under OMB control number 0910-0073.
V. Comments
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management (See ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at https://www.regulations.gov.
Dated: August 8, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-19686 Filed 8-13-13; 8:45 am]
BILLING CODE 4160-01-P